Dieci anni di utilizzo delle statine: adesione alla terapia e costi del trattamento farmacologico

Scandinavian Simvastin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–8

Pfeffer MA, Sack FM, Moye LA, et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. N Engl J Med 1996; 335: 1001–9

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentration: the LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease) Study group. Lancet 2002; 359: 1379–87

Shepherd J, Cobbe SM, Ford J, et al. Prevention of coronary heart disease with pravastatin in men hypercholesterolemia, West Of Scotland Coronary Prevention Study (WOSCOP). N Engl J Med 1995; 333: 1301–7

Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering and antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death. Eur Heart J 1999; 20: 725–41

Jackevicius CA, Mamdami M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462–7

Direzione Generale della Valutazione dei Medicinali e della Farmacovigilanza. L’uso dei farmaci in Italia. Rapporto Nazionale 2001. Roma: Ministero della Salute, 2002

WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Alterations and New ATC/DDDs. Copenhagen: WHO Regional Office for Europe, 2002

Osservatorio Nazionale sull’Impiego dei Farmaci. L’uso dei farmaci in Italia. Rapporto Nazionale anno 2001. Roma: Ministero della Salute, 2002

Osservatorio Nazionale sull’Impiego dei Farmaci. L’uso dei farmaci in Italia. Rapporto Nazionale I semestre 2003. Roma: Ministero della Salute, 2003

Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998; 317: 1134–5

Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229–33

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97

Cannon C, Braunwald E, McCabe C, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504

Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercolesterolaemia (ASAP): a prospective, randomized, double-bind trial. Lancet 2001; 357: 577–81

Nissen S, Murat Tuzcu E, Schoenhagen P, et al. Effect of intensive compared with moderate lipid lowering therapy on progression of coronary atherosclerosis. JAMA 2004; 291: 1071–80

Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–61

Larsen J, Vaccheri A, Andersen M, et al. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000; 49: 463–71

Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 375–8

Catalan V, LeLorier J. Predictors of long term persistence on statin in a subsidized clinical population. Value Health 2002; 3: 417–26

Applegate WB. Elderly patients’ adherence to statin therapy. JAMA 2002; 288: 495–7

Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (CURVES). Am J Cardiol 1998; 81: 582–7